DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for leiomyosarcoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeiomyosarcoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leiomyosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
kelch like ECH associated protein 1 (KEAP1) — KEAP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IXS · 1.48 Å · ligand (2R,3S)-3-[[(2S)-2-fluoranyl-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanoyl]amino]-2-methyl-3-(4-methylphenyl)propanoic acid (T6I). Experimental structure, not a prediction.
What the evidence adds up to
A 54-year-old woman with advanced caval leiomyosarcoma extending into the right atrium underwent surgical excision without deep hypothermic circulatory arrest, including right nephrectomy, adrenalectomy, and en-bloc vena cava resection with Gore-Tex graft. No operative complications occurred; she was extubated on postoperative day one with normal renal function. Final pathology showed high-grade leiomyosarcoma with negative margins, and she was well at latest follow-up. The authors concluded that resection offers the best chance of cure and is possible without deep hypothermic circulatory arrest.
A 65-year-old woman with rapidly progressive retroperitoneal pleomorphic leiomyosarcoma fully occupying the abdominal cavity underwent debulking surgery, but a residual tumour grew to approximately 22 cm within 38 days. She then received six cycles of doxorubicin and ifosfamide combination chemotherapy with maintained dose intensity, achieving a partial response, followed by about 50 Gy radiotherapy. This multimodal strategy yielded progression-free survival beyond 17 months with sustained symptomatic relief. The authors noted that maintaining dose intensity of chemotherapy and radiotherapy might contribute to overall tumour control.
A retrospective case series of 75 patients with extremity leiomyosarcoma surgically treated between 2000 and 2015 reported an overall survival of 60%. Forty-seven patients received (neo)adjuvant therapy. Infection occurred in 11 patients, seven associated with (neo)adjuvant radiotherapy; dermatological complaints occurred in 26 patients, ten associated with (neo)adjuvant radiotherapy. Local recurrence was seen in 11 patients (15%). The authors described favourable clinical outcome following (neo)adjuvant radiotherapy but called for larger databases to define the benefits of adjuvant therapy.
A 70-year-old man with metastatic leiomyosarcoma received nine lines of therapy over four years, including partial tumour resection, radiotherapy, and multiple systemic treatments. Comprehensive pancancer panel sequencing of the cancer tissue detected a loss-of-function mutation in a homologous recombination repair gene, enabling treatment with the PARP inhibitor olaparib. The addition of temozolomide, an alkylating agent whose effectiveness for this combination had previously been shown only for uterine leiomyosarcoma, proved effective in this male patient. The authors reported survival far greater than expected under approved standard therapy and emphasised the value of systematic molecular sequencing and presentation in a molecular tumour board. Still missing are prospective trials that confirm the benefit of PARP inhibitor combinations in nonuterine leiomyosarcoma with homologous recombination repair mutations, and the funding and patient stratification needed to run them.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cardiac Surgery · 2010 · 14 citations
Surgical Technique of Removal of Inferior Vena Cava Leiomyosarcoma Extending into the Right Atrium without Deep Hypothermic Circulatory Arrest
AbstractBACKGROUND: Leiomyosarcoma of the inferior vena cava is a rare tumor with potential for significant morbidity and mortality. Surgical extirpiration remains the optimal treatment choice. A case of caval leiomyosarcoma with right atrial extension is presented with management techniques and literature review. METHODS: A 54 year old woman with constitutional symptoms was found to have advanced caval leiomyosarcoma with atrial extension. Surgical excision was performed without deep hypothermic circulatory arrest (DHCA), including right nephrectomy, adrenalectomy, and en-bloc resection of the vena cava along with Gore-Tex interposition graft. RESULTS: There were no operative complications. The patient was extubated on postoperative day one. Renal function remained normal. Final pathology was high grade leiomyosarcoma. Margins were negative. The patient is well at latest follow up. CONCLUSION: Resection of extensive caval leiomyosarcoma allows the best chance of cure and is possible without DHCA. Perioperative planning and coordination and adherence to oncologic techniques is critical.
BMC Research Notes · 2014 · 5 citations · open access
Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report
AbstractBACKGROUND: Retroperitoneal sarcomas (RPS), such as pleomorphic leiomyosarcoma, often invade or displace vital organs in the abdominal cavity and exhibit an aggressive clinical course. Complete surgical resection of the tumor and preoperative radiotherapy and chemotherapies can be used for non-metastatic RPS. However, in case of huge retroperitoneal sarcoma fully occupying the abdominal cavity, surgical resection tends to be insufficient, resulting in poor outcomes. This report describes a case of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma that was favorably controlled by debulking surgery followed by combination chemotherapy and radiotherapy. CASE PRESENTATION: A 65-year-old Japanese woman developed abdominal discomfort due to a huge retroperitoneal tumor fully occupying the abdominal cavity. The immunohistochemical diagnosis was pleomorphic leiomyosarcoma with high-grade malignancy and aggressive proliferative features. Debulking surgery could be performed, but the small residual tumor had rapidly grown to an approximately 22 cm in length on the major axis within 38 days after the operation. The patient's general condition progressively declined. Combination chemotherapy, consisting of doxorubicin and ifosfamide, was successfully administered for six cycles while maintaining dose intensity. The best objective response was a partial response, and the chemotherapy was well tolerated. Approximately 50 Gy of radiotherapy was delivered to the remaining tumor. This multimodal strategy resulted in progression-free survival for more than 17 months and achieved sustained symptomatic relief. CONCLUSIONS: Multimodal therapy with debulking surgery, combination chemotherapy and radiotherapy controlled a rapidly progressive retroperitoneal pleomorphic leiomyosarcoma. Maintaining dose intensity of the chemotherapy and radiotherapy might contribute to overall tumor control.
Anticancer Research · 2020 · 4 citations · open access
Clinical Outcome of Surgically Treated Leiomyosarcoma of the Extremities: A Retrospective Overview
AbstractAIM: This study was interested in extremity leiomyosarcoma with focus on clinical outcome after surgery with or without adjuvant therapy. PATIENTS AND METHODS: A retrospective case series of all patients with leiomyosarcoma, surgically treated between 2000 and 2015 and a minimum follow-up of 2 years, was drawn from institutional databases in Belgium and the Netherlands. Postoperative complications were reported with the Radiation Therapy Oncology Group (RTOG) and the Henderson classification. RESULTS: Seventy-five patients were operated on, of whom 47 underwent (neo)adjuvant therapy. Infection was observed in 11 patients, seven associated with (neo)adjuvant radiotherapy. Dermatological complaints were observed in 26 patients, 10 associated with (neo)adjuvant radiotherapy. Overall survival was 60%. Local recurrence occurred in 11 (15%) patients. CONCLUSION: This study describes favourable clinical outcome following (neo)adjuvant radiotherapy. In the future, larger databases on leiomyosarcoma should enhance the power of these findings and define the benefits of adjuvant therapy in leiomyosarcoma.
Frontiers in Oncology · 2025 · 0 citations · open access
Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: a case report and review of the literature
AbstractLeiomyosarcoma is a malignant soft tissue tumor that still has a very poor prognosis in the metastatic stage, often lasting only several months. In addition to surgery and radiotherapy, the conventional treatment of this tumor entity is determined by chemotherapeutic regimes. Apart from anti-angiogenetically effective substances, hardly any targeted therapy options have been established. Here, we report the case of a 70-year-old man with metastatic leiomyosarcoma, who was able to be chronified by nine lines of oncological therapy over a period of four years, in addition to partial tumor resection and radiotherapy. The survival reported here is far greater than would be expected under approved standard therapy. Key to the long-term treatment of this patient was comprehensive pancancer panel sequencing (CCP, next-generation sequencing of genomic DNA) of the cancer tissue to search for molecular targets. This detected a loss-of-function mutation in a homologous recombination repair (HRR) gene, enabling treatment with the PARP inhibitor olaparib. Another special feature was the addition of the alkylating cytostatic agent temozolomide; the effectiveness of this combination therapy has so far only been shown for uterine leiomyosarcoma, but also proved to be an effective therapeutic strategy in the case of a male patient reported here. Despite high cumulative doses of previously applied chemotherapy, the targeted oncological treatment was tolerable and effective. The case report shows the high value of systematic molecular sequencing of cancer tissue and presentation in molecular tumor board for identification of molecular target structures for optimized palliative systemic therapy of metastatic leiomyosarcoma. In addition, the case report demonstrates that the combination therapy olaparib/temozolomide may also be an effective treatment approach for nonuterine leiomyosarcoma with HRR loss of function.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
